Stock Price and Market Movement
On 25 Nov 2025, Shree Ganesh Biotech India’s share price touched Rs.0.64, the lowest level recorded in its trading history. This price point is notably below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating persistent selling pressure. The stock’s daily change registered a decline of 1.54%, while the Sensex showed a marginal positive movement of 0.01% on the same day.
Examining the short-term performance, the stock declined by 7.25% over the past week, whereas the Sensex gained 0.27%. The one-month trend shows a 14.67% reduction in Shree Ganesh Biotech India’s price, compared to a 0.82% rise in the Sensex. Over three months, the stock’s value fell by 17.95%, while the benchmark index advanced by 4.00%.
Strong fundamentals, solid momentum, fair price – This Large Cap from the NBFC sector checks every box for our Top 1%. This should definitely be on your radar!
- - Complete fundamentals package
- - Technical momentum confirmed
- - Reasonable valuation entry
Long-Term Performance and Comparative Analysis
Over the one-year period, Shree Ganesh Biotech India’s stock price has declined by 38.46%, in stark contrast to the Sensex’s gain of 5.99%. The year-to-date figures mirror this trend, with the stock down 38.46% against the Sensex’s 8.66% rise. The three-year performance further emphasises the stock’s challenges, showing a drop of 64.84%, while the Sensex appreciated by 36.30% during the same period.
Looking at a five-year horizon, the stock’s value has contracted by 86.71%, whereas the Sensex has surged by 93.72%. Over a decade, Shree Ganesh Biotech India’s stock price has remained flat, with no recorded gains, while the Sensex has grown by 229.40%. These figures highlight the stock’s prolonged underperformance relative to the broader market.
Financial Health and Profitability Metrics
The company’s financial data for the nine months ending September 2025 reveals net sales of Rs.5.16 crores, reflecting a contraction of 44.64% compared to the previous period. Correspondingly, the profit after tax (PAT) stood at a loss of Rs.0.61 crores, also showing a decline of 44.64%. These figures indicate a reduction in revenue generation and profitability.
Shree Ganesh Biotech India’s ability to manage its debt obligations appears constrained, with an average EBIT to interest ratio of 0.91. This ratio suggests that earnings before interest and tax are insufficient to comfortably cover interest expenses. Additionally, the company’s average return on equity (ROE) is 2.62%, signalling limited profitability relative to shareholders’ funds.
The debtors turnover ratio for the half-year period is recorded at 0.00 times, indicating challenges in realising receivables efficiently. Furthermore, the company’s earnings before interest, tax, depreciation and amortisation (EBITDA) have been negative, underscoring the financial strain faced by the business.
Shareholding and Market Position
The majority of Shree Ganesh Biotech India’s shares are held by non-institutional investors. This ownership structure may influence liquidity and trading dynamics in the stock. The company operates within the Pharmaceuticals & Biotechnology sector, which has generally shown resilience; however, Shree Ganesh Biotech India’s performance has diverged significantly from sector trends.
Shree Ganesh Biotech India or something better? Our SwitchER feature analyzes this micro-cap Pharmaceuticals & Biotechnology stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Market Context and Valuation Considerations
Shree Ganesh Biotech India’s stock is trading at levels considered risky when compared to its historical valuations. The stock’s return over the past year stands at -38.46%, while profits have contracted by approximately 86.6%. This disparity highlights the challenges in maintaining earnings alongside stock price movements.
In comparison to the broader market and sector indices, the stock’s performance has been markedly subdued. The Pharmaceuticals & Biotechnology sector has generally exhibited steadier trends, whereas Shree Ganesh Biotech India’s share price has consistently lagged behind.
Summary of Key Challenges
The company’s financial indicators point to a period of sustained difficulty. Declining sales, negative profitability, and constrained debt servicing capacity have contributed to the stock’s fall to an all-time low. The absence of positive momentum across multiple time frames and the stock’s position below all major moving averages further illustrate the extent of the current situation.
While the broader market and sector indices have shown resilience and growth, Shree Ganesh Biotech India’s stock has experienced a prolonged downtrend, culminating in the recent historic low price.
Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →
